# Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07689643/  
OnCo record `nct07689643` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of [Ac-225]RTX-2358 run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.

## Summary

Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT07689643 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with 36 participants planned, started 2026-04-28. Conditions recorded: Metastatic Non-small Cell Lung Cancer. Interventions recorded: [177Lu]Lu-RTX-2358.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07689643
- Phase: 1
- Setting: A Single-Center, Prospective, Open-Label, Investigator-Initiated Study Evaluating the Safety, Biodistribution, Radiation Dosimetry, and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07689643: https://clinicaltrials.gov/study/NCT07689643

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [[Ac-225]RTX-2358](https://onco.cc/drugs/rtx-2358/)
- companies: [Ratio Therapeutics](https://onco.cc/companies/ratio-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07689643.json